Frontotemporal Dementia Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Alector, Oncolys BioPharma, Denali Therapeutics Inc, Passage Bio

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Frontotemporal Dementia pipeline constitutes 15+ key companies continuously working towards developing 20+ Frontotemporal Dementia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Frontotemporal Dementia Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Frontotemporal Dementia Market.

The Frontotemporal Dementia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Frontotemporal Dementia Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Frontotemporal Dementia treatment therapies with a considerable amount of success over the years.

*
Frontotemporal Dementia companies working in the treatment market are Deep Genomics, Asceneuron SA, AviadoBio, CAMP4 Therapeutics, Neurimmune, Prevail Therapeutics, Passage Bio, Transposon Therapeutics, Alector Inc., and others, are developing therapies for the Frontotemporal Dementia treatment

*
Emerging Frontotemporal Dementia therapies in the different phases of clinical trials are- Research programme CNS Therapies, Research Program M1 PAM, AVB-101, Research programme CNS, NI308, PR006, PBFT02, TPN-101, AL001, and others are expected to have a significant impact on the Frontotemporal Dementia market in the coming years.

*
In May 2025, Vesper Bio ApS announced that it has achieved a key enrollment milestone in the Phase Ib/IIa portion of its ongoing SORT-IN-2 trial for its lead candidate, VES001. This study focuses on asymptomatic individuals carrying a mutation in the progranulin (GRN) gene, which is linked to a major genetically driven form of frontotemporal dementia (FTD), known as FTD-GRN.

*
In April 2025, At the 2025 American Academy of Neurology (AAN) Annual Meeting, held April 5-9 in San Diego, California, researchers shared baseline characteristics of participants in the INFRONT-3 study (NCT04374136), a Phase 3 trial evaluating Alector's investigational latozinemab for frontotemporal dementia (FTD) caused by GRN mutations. This pivotal, multicenter, randomized, double-blind, placebo-controlled 96-week trial is expected to provide insights into disease progression in this specific patient population.

*
In January 2025, Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company dedicated to treating neurodegenerative diseases, has provided updated findings from its ongoing Phase 1/2 upliFT-D trial evaluating PBFT02 for frontotemporal dementia (FTD) with granulin (GRN) mutations. Additionally, the company highlighted key upcoming milestones and announced the successful completion of process development and scale-up for a suspension-based manufacturing process of PBFT02. As the program progresses, Passage Bio has reassessed its operational requirements and will shift to an outsourced analytical testing model.

*
In November 2024, CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company dedicated to developing therapies for age-related neurological conditions, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its oral investigational treatment, neflamapimod, for frontotemporal dementia (FTD).

*
In September 2024, Vesper Bio shared findings from a Phase I trial evaluating VES001, a potential disease-modifying therapy for frontotemporal dementia (FTD), specifically in patients with progranulin gene (GRN) mutations. The first participant was dosed in December last year. The study, involving 78 healthy volunteers, aimed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamic target engagement of VES001.

*
In April 2024, AviadoBio has announced that the initial patient has received treatment in the Phase I/II ASPIRE-FTD trial, which is assessing the company's experimental gene therapy, AVB-101, for individuals with frontotemporal dementia (FTD) caused by progranulin (GRN) gene mutations (FTD-GRN).

*
In February 2024, Transposon Therapeutics has released interim findings from its Phase II trial of TPN-101, focusing on patients with amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD) associated with hexanucleotide repeat expansions in the C9orf72 gene (C9orf72-related ALS/FTD).

*
In February 2024, Alector, Inc. and GSK plc have reported that the U.S. Food and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to latozinemab for its potential use in treating frontotemporal dementia associated with a progranulin gene mutation (FTD-GRN).

Frontotemporal Dementia Overview

Frontotemporal dementia (FTD) is a collective term for a set of disorders caused by gradual loss of function in the brain's frontal and temporal lobes. These brain regions are crucial for behavior, language, and decision-making skills.

Get a Free Sample PDF Report to know more about Frontotemporal Dementia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/frontotemporal-dementia-pipeline-insight [https://www.delveinsight.com/report-store/frontotemporal-dementia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Frontotemporal Dementia Drugs Under Different Phases of Clinical Development Include:

*
Research programme CNS Therapies: Deep Genomics

*
Research Program M1 PAM: Asceneuron SA

*
AVB-101: AviadoBio

*
Research programme CNS: CAMP4 Therapeutics

*
NI308: Neurimmune

*
PR006: Prevail Therapeutics

*
PBFT02: Passage Bio

*
TPN-101: Transposon Therapeutics

*
AL001: Alector Inc.

Frontotemporal Dementia Route of Administration

Frontotemporal Dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Intra-articular

*
Intraocular

*
Intrathecal

*
Intravenous

*
Ophthalmic

*
Oral

*
Parenteral

*
Subcutaneous

*
Topical

*
Transdermal

Frontotemporal Dementia Molecule Type

Frontotemporal Dementia Products have been categorized under various Molecule types, such as

*
Oligonucleotide

*
Peptide

*
Small molecule

Frontotemporal Dementia Pipeline Therapeutics Assessment

*
Frontotemporal Dementia Assessment by Product Type

*
Frontotemporal Dementia By Stage and Product Type

*
Frontotemporal Dementia Assessment by Route of Administration

*
Frontotemporal Dementia By Stage and Route of Administration

*
Frontotemporal Dementia Assessment by Molecule Type

*
Frontotemporal Dementia by Stage and Molecule Type

DelveInsight's Frontotemporal Dementia Report covers around 20+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Frontotemporal Dementia product details are provided in the report. Download the Frontotemporal Dementia pipeline report to learn more about the emerging Frontotemporal Dementia therapies [https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Frontotemporal Dementia Therapeutics Market include:

Key companies developing therapies for Frontotemporal Dementia are - Alector Inc., Transposon Therapeutics, Oncolys BioPharma, Denali Therapeutics Inc, Passage Bio, Inc., Prevail Therapeutics, Wave Life Sciences, and others.

Frontotemporal Dementia Pipeline Analysis:

The Frontotemporal Dementia pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Frontotemporal Dementia with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Frontotemporal Dementia Treatment.

*
Frontotemporal Dementia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Frontotemporal Dementia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Frontotemporal Dementia market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Frontotemporal Dementia drugs and therapies [https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Frontotemporal Dementia Pipeline Market Drivers

*
Increasing prevalence of geriatric population, increasing drug development grants, increasing collaborations among companies are some of the important factors that are fueling the Frontotemporal Dementia Market.

Frontotemporal Dementia Pipeline Market Barriers

*
However, lack of proper diagnosis, higher chances of misunderstanding with Alzheimer's disease and other factors are creating obstacles in the Frontotemporal Dementia Market growth.

Scope of Frontotemporal Dementia Pipeline Drug Insight

*
Coverage: Global

*
Key Frontotemporal Dementia Companies: Deep Genomics, Asceneuron SA, AviadoBio, CAMP4 Therapeutics, Neurimmune, Prevail Therapeutics, Passage Bio, Transposon Therapeutics, Alector Inc., and others

*
Key Frontotemporal Dementia Therapies: Research programme CNS Therapies, Research Program M1 PAM, AVB-101, Research programme CNS, NI308, PR006, PBFT02, TPN-101, AL001, and others

*
Frontotemporal Dementia Therapeutic Assessment: Frontotemporal Dementia current marketed and Frontotemporal Dementia emerging therapies

*
Frontotemporal Dementia Market Dynamics: Frontotemporal Dementia market drivers and Frontotemporal Dementia market barriers

Request for Sample PDF Report for Frontotemporal Dementia Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Frontotemporal Dementia Report Introduction

2. Frontotemporal Dementia Executive Summary

3. Frontotemporal Dementia Overview

4. Frontotemporal Dementia- Analytical Perspective In-depth Commercial Assessment

5. Frontotemporal Dementia Pipeline Therapeutics

6. Frontotemporal Dementia Late Stage Products (Phase II/III)

7. Frontotemporal Dementia Mid Stage Products (Phase II)

8. Frontotemporal Dementia Early Stage Products (Phase I)

9. Frontotemporal Dementia Preclinical Stage Products

10. Frontotemporal Dementia Therapeutics Assessment

11. Frontotemporal Dementia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Frontotemporal Dementia Key Companies

14. Frontotemporal Dementia Key Products

15. Frontotemporal Dementia Unmet Needs

16 . Frontotemporal Dementia Market Drivers and Barriers

17. Frontotemporal Dementia Future Perspectives and Conclusion

18. Frontotemporal Dementia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=frontotemporal-dementia-pipeline-2025-moa-roa-fdaapproved-drugs-and-clinical-trial-progress-assessment-by-delveinsight-alector-oncolys-biopharma-denali-therapeutics-inc-passage-bio]
Phone: +Gaurav Bora
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.